American Century Companies
SMMT icon

American Century Companies’s Summit Therapeutics SMMT Stock Holding History

American Century Companies’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,971
Closed -$231K – 2951
2024
Q4 		$231K Buy
+12,971
New +$251K ﹤0.01% 2755
2024
Q1 		– Sell
-77,074
Closed -$201K – 2960
2023
Q4 		$201K Buy
+77,074
New +$159K ﹤0.01% 2689

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

American Century Companies's SMMT Position: Q1 2025 in Review

American Century Companies sold out of Summit Therapeutics (SMMT) in Q1 2025, closing a stake of 12,971 shares — an estimated $231K sold.

American Century Companies first reported a position in SMMT in Q4 2023 and held it in 2 quarters. The position peaked at $231K in Q4 2024. 212 funds tracked by Wall St. Rank hold SMMT as of Q1 2025.

  • American Century Companies reported no remaining Summit Therapeutics position as of Q1 2025 after selling out during the quarter.
  • American Century Companies sold 12,971 Summit Therapeutics shares in Q1 2025, an estimated $231K.
  • American Century Companies first reported a position in Summit Therapeutics in Q4 2023 and held it in 2 quarters.
  • American Century Companies's Summit Therapeutics position peaked at $231K in Q4 2024.
  • 212 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2025.

Based on American Century Companies's 13F filing for Q1 2025, filed 13 May 2025.